http://www.fda.gov/cder/orange/appendix_a.txt 3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
EMRindex2003.qxd See Emergency Medical Treatment and Active Labor Act Encephalopathy, drug- induced, 12: 165- 166 Endocarditis, 6: 80- 81 classification of, 15: 201- 202, 201t Duke diagnostic criteria for, 15: 202, 202t infectious (IE), 15: 201- 203, 202t Endotracheal tube introducer, Trauma 2: 7 Endotracheal tube lightwand unit (ETT- LW), Trauma 2: 6- 7 Endotracheal tubes, Trauma 1: 4t Endovaginal...
author: mcintosht
EMRindex2003.qxd page 6
author: mcintosht
http://www.fda.gov/cder/ogd/rld/RLD_LABELING_APPROVED_FEB_1999.HTML Firm Date BRETHINE Terbutaline Sulfate Tablet 17-849 032 Novartis Pharms 2-Feb-1999 CHLOROMYCETIN Chloramphenicol Opth Ointment 50-156 038 Parkedale 3-Feb-1999 PRILOSEC Omeprazole Delayed-Release Capsule 19-810 057 Astra Merck 3-Feb-1999 TRANSDERM-NITRO Nitroglycerin Transdermal System 20-144 018 Novartis Pharms 3-Feb-1999 PRIMAXIN Cilastatin Sodium/Imipenem Injection 50-587 50-630...
sgw8293.tmp page 12
author: fda
sgw8293.tmp page 5
author: fda
sgw8293.tmp page 2
author: fda
Geron - Press Releases GERON CORPORATION ACQUIRES PATENT PORTFOLIO FROM LYNX THERAPEUTICS INTELLECTUAL PROPERTY INCLUDES COMPOSITION AND PROCESS CLAIMS FOR AMIDATE OLIGONUCLEOTIDES MENLO PARK, CA – March 6, 2002--Geron Corporation (Nasdaq: GERN) announced today that it has acquired from Lynx Therapeutics (Nasdaq: LYNX) all of Lynx’s patents relating to oligonucleotides containing...
Geron - Press Releases GERON CORPORATION ACQUIRES PATENT PORTFOLIO FROM LYNX THERAPEUTICS INTELLECTUAL PROPERTY INCLUDES COMPOSITION AND PROCESS CLAIMS FOR AMIDATE OLIGONUCLEOTIDES MENLO PARK, CA – March 6, 2002--Geron Corporation (Nasdaq: GERN) announced today that it has acquired from Lynx Therapeutics (Nasdaq: LYNX) all of Lynx’s patents relating to oligonucleotides containing...
EMRindex2003.qxd page 2
author: mcintosht
JCCG Winter 1998 Molecular Builders Molecular Builders by S
Home: News GERON CORPORATION ACQUIRES PATENT PORTFOLIO FROM LYNX THERAPEUTICS ******************************************* INTELLECTUAL PROPERTY INCLUDES COMPOSITION AND PROCESS CLAIMS FOR AMIDATE OLIGONUCLEOTIDES MENLO PARK, CA – March 6, 2002--Geron Corporation (Nasdaq: GERN) announced today that it has acquired from Lynx Therapeutics (Nasdaq: LYNX) all of Lynx’s patents...
